Is this neuroprotective drug good for my glaucoma patients? Some key factors in clinical decision-making

Canadian Journal of Ophthalmology

Volumn 42, Issue 3, 2007, Pages 418-420

  Goldberg, Ivan ^a,b  

^a UNIVERSITY OF SYDNEY   (Australia)

^b NONE   (Australia)

Author keywords

Glaucoma; Guidelines; Management; Neuroprotection

Indexed keywords

NEUROPROTECTIVE AGENT;

CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; COST BENEFIT ANALYSIS; DRUG DELIVERY SYSTEM; DRUG EFFICACY; GLAUCOMA; HEALTH CARE PERSONNEL; HUMAN; MEDICAL ASSESSMENT; MEDICAL DECISION MAKING; MORTALITY; NONHUMAN; PRACTICE GUIDELINE; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; VISION;

EID: 34250676048     PISSN: 00084182     EISSN: 17153360     Source Type: Journal    
DOI: 10.3129/I07-075     Document Type: Conference Paper

References (6)

1. Ocular Hypertension Treatment Study Group; European Glaucoma Prevention Study Group; Gordon MO, Torri V, Miglior S, et al. Validated prediction model for the development of primary open-angle glaucoma in individuals with ocular hypertension. Ophthalmology 2007;114:10-9.
2. Leske MC, Heijl A, Hyman L, Bengtsson B, Komaroff E. Factors for progression and glaucoma treatment: the Early Manifest Glaucoma Trial. Curr Opin Ophthalmol 2004;15:102-6.
3. Anderson DR, Drance SM, Schulzer M, Collaborative Normal-Tension Glaucoma Study Group. Factors that predict the benefit of lowering intraocular pressure in normal tension glaucoma. Am J Ophthalmol 2003;136:820-9.
4. Schwartz M, Yoles E, Levin LA. 'Axogenic' and 'somagenic' neurodegenerative diseases: definitions and therapeutic implications. Mol Med Today 1999;5:470-3.
5. South East Asia Glaucoma Interest Group (SEAGIG). Asia Pacific Glaucoma Guidelines. 2003. Available: http://seagigimages/stories/downloads/ APGGuidelinesNMview.pdf (accessed 2007 Apr 25).
6. European Glaucoma Society. Terminology and Guidelines for Glaucoma. 2nd ed. 2003. Available: www.eugs.org (accessed 2007 Apr 25).